Stock analysts expect Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to report earnings per share (EPS) of $1.96 for the current fiscal quarter, according to Zacks. Nine analysts released earnings estimates for Zimmer Biomet, with estimates ranging from $1.90 to $1.99. Zimmer Biomet reported earnings per share of $2.11 in the same quarter last year, which would indicate a negative 7.1% year-over-year growth rate. The company is expected to release its next results before the market opens on Monday, February 7.

According to Zacks, analysts expect Zimmer Biomet to report annual earnings of $7.38 per share for the current fiscal year, with EPS estimates ranging from $7.32 to $7.41. For the next fiscal year, analysts expect the company to post earnings of $8.08 per share, with EPS estimates ranging from $7.72 to $8.48. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Zimmer Biomet.

Zimmer Biomet Inc (NYSE:ZBH) last released its results on Thursday, November 4. The medical equipment supplier reported EPS of $1.81 for the quarter, beating Thomson Reuters consensus estimate of $1.76 by $0.05. Zimmer Biomet achieved a net margin of 10.39% and a return on equity of 12.67%. The company posted revenue of $1.92 billion in the quarter, versus $1.94 billion expected by analysts. In the same quarter last year, the company achieved EPS of $1.81. The company’s revenue fell 0.3% year-over-year.

ZBH has been the subject of several recent analyst reports. Needham & Company LLC downgraded Zimmer Biomet shares from a “strong buy” rating to a “buy” rating and reduced its target price for the stock from $175.00 to $158.00 in a rating note. research from Thursday, December 9. Citigroup cut its price target on Zimmer Biomet shares from $188.00 to $175.00 and set a “buy” rating for the company in a Friday, Nov. 5, report. Wells Fargo & Company downgraded shares of Zimmer Biomet from a “weighted” rating to an “underweight” rating and reduced its price target for the company from $170.00 to $124.00 in a published report Wednesday. BTIG Research downgraded shares of Zimmer Biomet from a “buy” rating to a “neutral” rating in a Monday, January 10, report. Finally, Morgan Stanley downgraded shares of Zimmer Biomet from an “overweight” rating to an “equally weighted” rating and cut its price target for the company from $165.00 to $145.00 in a Friday report. January 7. One equity research analyst rated the stock with a sell rating, nine gave the company a hold rating and thirteen gave the company a buy rating. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $166.60.

Separately, insider Sang Yi sold 2,800 shares of Zimmer Biomet in a trade dated Tuesday, December 14. The shares were sold at an average price of $124.14, for a total transaction of $347,592.00. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website. Insiders hold 0.56% of the shares of the company.

Institutional investors and hedge funds have recently increased or reduced their stakes in the stock. Tompkins Financial Corp acquired a new equity stake in Zimmer Biomet in the third quarter worth approximately $36,000. US Asset Management LLC acquired a new equity stake in Zimmer Biomet in the third quarter worth approximately $37,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in Zimmer Biomet shares by 133.3% in the third quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 280 shares of the medical equipment supplier worth $41,000 after acquiring an additional 160 shares in the last quarter. Herold Advisors Inc. acquired a new equity stake in Zimmer Biomet in the third quarter worth approximately $40,000. Finally, Tradewinds Capital Management LLC increased its position in Zimmer Biomet shares by 55.2% in the third quarter. Tradewinds Capital Management LLC now owns 281 shares of the medical equipment supplier worth $41,000 after acquiring 100 additional shares in the last quarter. 88.09% of the shares are currently held by institutional investors and hedge funds.

Shares of ZBH traded down $1.16 during the midday session on Wednesday, hitting $125.19. The stock had a trading volume of 22,040 shares, compared to an average volume of 1,596,280. Zimmer Biomet has a fifty-two week low of $116.60 and a fifty-two week high of 180, $36. The company has a market capitalization of $26.15 billion, a PE ratio of 32.30, a PEG ratio of 2.34 and a beta of 1.25. The company has a debt ratio of 0.51, a current ratio of 1.81 and a quick ratio of 0.95. The company’s 50-day simple moving average is $126.89 and its 200-day simple moving average is $141.56.

The company also recently declared a quarterly dividend, which will be paid on Monday, January 31. Shareholders of record on Tuesday, December 28 will receive a dividend of $0.24 per share. The ex-dividend date is Monday, December 27. This represents a dividend of $0.96 on an annualized basis and a dividend yield of 0.77%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.68%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It operates through the following segments: Americas and Global, EMEA and Asia-Pacific. The Americas and Global segment includes the United States and includes other North, Central and South American markets for all product categories as well as the dental division’s global results.

Recommended Story: Forex

Get a Free Copy of Zacks’ Research Report on Zimmer Biomet (ZBH)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Zimmer Biomet right now?

Before you consider Zimmer Biomet, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Zimmer Biomet wasn’t on the list.

While Zimmer Biomet currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here